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Abstract
Background: Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based
chemotherapy) provides a small survival advantage. However the drawback is the accompanying systemic toxicity, which
targeted treatments may overcome. This study aimed to evaluate the safety and tolerability of KAb201, an anti-
carcinoembryonic antigen monoclonal antibody, labelled with I131 in pancreatic cancer (ISRCTN 16857581).
Methods:  Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were
randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route. The dose limiting toxicities
within each group were determined. Patients were assessed for safety and efficacy and followed up until death.
Results: Between February 2003 and July 2005, 25 patients were enrolled. Nineteen patients were randomised, 9 to the
intravenous and 10 to the intra-arterial arms. In the intra-arterial arm, dose limiting toxicity was seen in 2/6 (33%) patients
at 50 mCi whereas in the intravenous arm, dose limiting toxicity was noted in 1/6 patients at 50 mCi, but did not occur
at 75 mCi (0/3).
The overall response rate was 6% (1/18). Median overall survival was 5.2 months (95% confidence interval = 3.3 to 9
months), with no significant difference between the intravenous and intra-arterial arms (log rank test p = 0.79). One
patient was still alive at the time of this analysis.
Conclusion: Dose limiting toxicity for KAb201 with I131 by the intra-arterial route was 50 mCi, while dose limiting
toxicity was not reached in the intravenous arm.
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Background
Pancreatic cancer has an exceptionally poor prognosis
with overall 5 year survival rates ranging from 3 to 5% [1-
4]. The majority of patients present with advanced disease
with a median life expectancy of 3 to 10 months [5]. Gem-
citabine is the standard first-line agent for the treatment of
advanced pancreatic cancer [6]. A recent randomised con-
trolled trial has shown significant improvement in sur-
vival by the addition of capecitabine to gemcitabine
compared to gemcitabine alone [7]. Other agents that add
activity to gemcitabine are erlotinib [8] and the platins [7]
but the advantage is small. In the light of the poor prog-
nosis of this condition even with palliative chemotherapy,
the search is on for better ways to treat this disease. Novel
agents and newer routes such as regional delivery are
being targeted, in the hope of finding a treatment with
better efficacy and less toxicity than conventional chemo-
therapy.
One novel approach is to use monoclonal antibodies con-
jugated with radionuclides, resulting in better targeting of
the tumour [9]. The radiation component has a bystander
effect, with killing of adjacent unbound cells. The greater
concentration of the drug within the tumour may have the
advantage of lessening toxicity to normal tissue, the latter
being a factor that limits the dosage and effectiveness of
systemically administered agents [10].
Carcino-embryonic antigen (CEA), a glycoprotein, is a
tumour-associated antigen and elevated levels are
detected in the cell membrane of tumours derived from
epithelium [11-14]. Monoclonal antibodies to this anti-
gen have been employed in clinical trials for several appli-
cations, such as radio-immunotherapy, antibody-directed
enzyme prodrug therapy and radio-immunoguided sur-
gery [15-17].
Anti CEA monoclonal antibodies have been employed for
radio-immunotherapy (RIT) in the treatment of colorectal
cancer, both in the palliative and adjuvant settings
[16,17]. One phase II trial of 30 patients, using anti CEA
monoclonal antibody, bound to I131, concluded that this
mode of treatment was safe and effective, with toxicity
being limited to mild and transient leukopenia and
thrombocytopenia [16]. Locoregional delivery of chemo-
therapy has been reported in both pancreatic cancer and
colorectal liver metastases, with improved overall survival
and reduced toxicity when compared to systemic chemo-
therapy [18,19] in randomised controlled trials.
CEA is overexpressed in over 90% of pancreatic cancers,
and represents a potential target for immunotherapy [20],
although no completed clinical trial has been reported in
pancreatic malignancy so far [21]. We conducted this
phase I/II trial employing targeted radioimmunotherapy
for cancers of the head of the pancreas, using anti-CEA
monoclonal antibody KAb201 radiolabelled with
Iodine131, administered either intravenously or intra-arte-
rially via the gastroduodenal artery. The rationale for
inclusion of an intra-arterial arm was the presumed
greater concentration of the study drug at the target site,
with the possible translation into greater efficacy coupled
with the advantage of reduced toxicity secondary to
regional delivery.
Methods
This study was open to recruitment from February 2003 to
July 2005 at a single centre.
Eligibility
Patients with locally advanced or metastatic adenocarci-
noma of the head of the pancreas were eligible. The inclu-
sion criteria were age > 18 years, histological or cytological
proof, at least one confirmed and measurable tumour site
in the head of pancreas, Karnofsky performance status
(KPS) ≥ 70 and life expectancy of at least three months.
Patients who had undergone prior treatment were
enrolled into the trial, provided there was a month's gap
between the radiotherapy/chemotherapy (preceding six
weeks for nitrosoureas).
Patients were excluded if there was haematological
impairment, worsening hepatic impairment or significant
renal dysfunction. Other exclusion criteria were known
immunological reactions to previously administered anti-
bodies, proteins or iodine, previous external beam radio-
therapy to maximal tolerable levels to any critical organ
and treatment with any other clinical trial medication
within the preceding three months.
Following confirmation of eligibility, patients were ran-
domised to receive the study drug by either the intra-arte-
rial or intravenous route, using computer generated
random numbers. The study was not blinded.
Monoclonal antibody (MAb)
KAb201 is a human-sheep chimaeric monoclonal anti-
body [22] against CEA, produced by a pharmaceutical
company (and study sponsor) Xenova Biomedix [23]. The
linking of the radioisotope to the MAb helps detect and
treat potential sites of disease. Iodine131 was chosen as its
half-life is close to the expected retention of the MAb at
the tumour site, its β emission can kill tumours over a
range of up to 40 cell diameters and its γ emission can
help in imaging the biodistribution.
An earlier phase I study carried out on 10 patients with
metastatic colorectal cancer using KAb201 with I131 foundBMC Cancer 2009, 9:66 http://www.biomedcentral.com/1471-2407/9/66
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the study drug to be well tolerated, with no drug related
adverse events, good localisation at the tumour site and
no antigen response in 9 patients [24].
Following this pilot study, the current phase I/II trial was
designed for pancreatic cancer after an in vitro study,
which yielded a sensitivity of 83% and specificity of 95%
for staining with Kab 201. In vitro studies had been con-
ducted by Xenova Biomedix and these showed specificity
of the antibody for tumour tissue but not for normal tis-
sue.
Radiolabelling for the pretherapy dose was done at the
local Nuclear Medicine department, using the Iodogen
method. Each 1 mg of KAb201 was labelled with 10 mCi
of I131, prepared up to 24 hours before administration.
Quality control was assessed using Mini TLC, aiming for
labelling efficiency of > 60%. The therapeutic dose was
prepared by Vrije University, Amsterdam, Netherland. The
activity of the I131 KAb 201 was assessed by the local
Nuclear Medicine Department prior to administration.
The stability of the radio labelling was > 90%.
Study design
Following informed consent, patients underwent clinical
evaluation, blood tests for haematological and biochemi-
cal assessment, tumour markers (CEA and CA19-9 levels),
baseline evaluation of anti-sheep (HASA) and anti-chi-
maeric (HACA) antibody and radioactivity levels. Tumour
size and extent were assessed by multi-detector computed
tomography (CT) of the chest, abdomen and pelvis and/
or F18 positron emission tomography (PET).
Pre therapy dose with 2 mCi of I131-Kab201 was adminis-
tered via the intended therapeutic route [25]. Intra-arterial
drug delivery was either through a temporary catheter
inserted at angiography using a 2.5 French prograde
microcatheter (Terumo, Belgium) into the gastroduode-
nal artery or via a permanent catheter, a Port-A-Cath sin-
gle-lumen implantable vascular access system (SIMS
Deltec, Inc., St. Paul, Minnesota, USA), which was
inserted into the gastroduodenal artery in patients who
required palliative bypass surgery. Intravenous drug deliv-
ery was via a standard intravenous line (20 or 22 gauge
Venflon). Twenty-four hours later, gamma camera static
and single photon emission computerised tomography
(SPECT) scans were performed to check for uptake of I131
in the tumour. This pre therapy check scan was done to
assess for uptake of I131 KAb201 in the primary and/or sec-
ondary tumour. If the scan was positive, the patient
received the therapy dose 5–7 days later and if there was
no uptake, the patient was withdrawn from the trial.
At each dose level, six patients were to be treated, three
patients per administration route (intravenous or intra-
arterial). Following the therapy dose, patients were iso-
lated for at least five days, in keeping with local radiation
safety measures. Repeat gamma camera and SPECT scans
were performed a week after treatment to assess localisa-
tion of I131 KAb201 post-therapy.
Patients were followed up 2, 5, 7, 11, 14, 28, 42, 60 and
90 days post- treatment. The blood tests undertaken dur-
ing follow up are summarised in Table 1. Analyses of
blood results and urinalysis were done at a single inde-
pendent laboratory (Pivotal Laboratory, York) except for
radioactivity levels, which were evaluated in the local
Nuclear Medicine Department of the Royal Liverpool Uni-
versity Hospital.
CT and PET scans were repeated at 1 and 3 months post
treatment. Response was evaluated using the Response
Evaluation Criteria in Solid Tumours (RECIST) criteria
[2,26]. If progressive disease was seen on the one month
post treatment scans, patients were allowed to withdraw
from the trial treatment and be referred for palliative
chemotherapy. These patients were followed up for ongo-
ing toxicity, if any, as well as survival.
Primary and secondary endpoints
The primary endpoints were safety, tolerability and level
at which dose limiting toxicity occurred. The secondary
endpoints were to assess the pharmacokinetics, antigenic-
ity, efficacy and overall survival.
Safety was tolerability were assessed by clinical evalua-
tion, Karnofsky performance status, urinalysis and blood
Table 1: Blood test schedule following treatment with I131 KAb201
Blood test Time points
Haematology Day of treatment and days 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
Biochemistry Day of treatment and days 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
Pharmacokinetics and radioactivity levels Days 1, 2, 5, 7, 11, 14, 28, 42, 60 and 90 post treatment
HASA/HACA Days 14, 28, 42, 60 and 90 post treatment
Serum CEA/CA19-9 Days 28, 60 and 90 post treatment
CEA complexing assay 6 hours post dosimetry
HASA = Human antisheep antibody; HACA = Human anti-chimaeric antibody; CEA = Carcino-Embryonic antigenBMC Cancer 2009, 9:66 http://www.biomedcentral.com/1471-2407/9/66
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tests (Table 1) and adverse events (AE) were graded by the
Common Toxicity Criteria (CTC) version 2 [27].
Dose limiting toxicity (DLT) was defined as grade 4 neu-
tropenia lasting for 7 or more days, febrile neutropenia,
platelet count < 25 × 109/L or counts between 25 × 109/L
to 50 × 109/L associated with bleeding requiring transfu-
sion, grade 3 or greater nausea despite adequate anti-
emetics and any other grade 3 or 4 adverse events. If a DLT
occurred in one of three patients, then a further three
patients were treated at that dose level and route. Dose
escalation was stopped if DLTs were seen in two or more
patients.
Pharmacokinetics of both the monoclonal antibody
KAb201 (frozen serum samples sent for analyses to
Huntingdon Life Sciences, Cambridgeshire, UK) and radi-
oiodine were studied (count done at local Nuclear Medi-
cine department, using a gamma camera calibrated for
I131), while antigenicity was assessed by estimating the
Human anti-sheep antibody (HASA) and Human anti-
chimaeric antibody (HACA) levels (frozen serum samples
sent for analyses to Huntingdon Life Sciences, Cambridge-
shire, UK).
Statistical Analyses
The number (and percentage) of patients experiencing
each adverse event were tabulated along with the number
(and percentage) of occurrences of each event. Time to
occurrence of first haematological toxicity was calculated
from date of pre therapy dose to date of haematological
toxicity (all grades) or the date of the last follow-up if cen-
sored. Overall survival was calculated from the date of
randomisation to death or the censor date. Time to event
data were analysed using the method of Kaplan and Meier
[28] and presented graphically with median (95% confi-
dence interval) data. The log rank test was used to assess
differences across groups according to the route of admin-
istration, KPS, tumour stage (locally advanced versus met-
astatic disease) and prior treatment. A post-hoc analysis
exploring the effect of baseline body surface area (BSA in
cm2) on time to haematological toxicity (all grades) was
undertaken using a Cox proportional hazards regression
model.
Pharmacokinetics of KAb201 and I131 were assessed using
a single compartment model with instantaneous intrave-
nous bolus and first order elimination rate to model both
the therapeutic dose and radioactivity plasma concentra-
tions. Area under the curve, Cmax, volume of distribution
and rate of elimination were estimated.
Overall response rate (any partial or complete response)
was summarised as a number/percentage.
Conduct of the study
Written informed consent was obtained from all patients
prior to entry to the study. The study was conducted
according to International Conference on Harmonisation
(ICH) on the topic Good Clinical Practice (GCP) guide-
lines. Ethical approval to carry out this study was given by
the Liverpool Local Research Ethics Committee. The trial
was conducted to conform to the principles of the Decla-
ration of Helsinki.
Results
Patient characteristics
Twenty five patients were screened between February
2003 and July 2005. Six patients were screening failures
and the other 19 patients were randomised, nine to the
intravenous arm and 10 to the intra-arterial arm (Table 2).
There was no loss to follow up.
Table 2: Patient characteristics (randomised patients)
Intra-venous
(n = 9)
Intra-arterial
(n = 10)
Total
(n = 19)
Age, years
median ((25th, 75th centile) min, max 60 (59,60) 53–66 59 (55,63) 47–67 60 (57,63) 47–67
Karnofsky Performance Status
Score ≤ 80 3 (33%) 7 (70%) 10 (53%)
Score ≥ 90 6 (67%) 3 (30%) 9 (47%)
Stage
IVa 2 (22%) 6 (60%) 8 (42%)
IVb 7 (78%) 4 (40%) 11 (58%)
Previous treatment
3 (33%)φ 1 (10%)ξ 4 (21%)
Time from diagnosis to randomisation, days
median ((25th, 75th centile) 84 (60,203) 37 (16,115) 77 (25,177)
min, max 27–316 2–256 2–316
φ one patient each had received: gemcitabine plus oxaliplatin 6 cycles, gemcitabine 8 cycles and gemcitabine 7 cycles
ξgemcitabine 3 cycles.BMC Cancer 2009, 9:66 http://www.biomedcentral.com/1471-2407/9/66
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Four patients had received prior chemotherapy, three of
whom had progressed on this prior treatment. One
patient had regression of disease following chemotherapy
(degree of response not evaluated) prior to enrolment
onto the trial. Median time from diagnosis to entry into
trial was 77 days (range = 25 to 177 days), and in those
with previous treatment, this was 247 days (range = 199
to 311 days).
Treatment summary
Seventeen patients received the pre therapy dose, nine by
the intravenous route and eight by intra-arterial route
(three via Port-A-Cath and five via a temporary catheter
placed at angiography). Two patients could not undergo
pre therapy dose due to problems with I131 availability.
Pre therapy scan uptake was seen in 16 out of 17 patients
with lack of uptake occurring in one patient in the intra-
arterial group. This patient was hence not given the ther-
apy dose and was excluded from toxicity and efficacy anal-
ysis. Post-therapy uptake was seen in all 18 patients.
Primary end point
Dose limiting toxicity (DLT) was observed in none out of
three patients at 45 mCi and two out of six patients at 50
mCi in the intra-arterial arm and one out of six patients at
50 mCi and none out of three patients at 75 mCi in the
intravenous arm (Figure 1).
The most common adverse event was haematological tox-
icity (all grades), seen in 17/18 patients (8/9 in the intra-
arterial arm and 9/9 in the intravenous arm). One patient
received treatment with granulocyte monocyte colony
stimulating factor for febrile neutropenia. The median
(95% Confidence Interval) time to occurrence of haema-
tological toxicity was 24 (12 to 40) days, with an earlier
onset in the intra-arterial arm (21 (12 to 34) days) com-
pared to the intravenous arm (35 (12 to 42) days),
although this difference was not statistically significant
(log rank p = 0.92). A Cox regression model suggested a
significant (p = 0.022) relationship between body surface
area in cm2 and time to first haematological toxicity (all
grades), with a hazard ratio (HR) of 0.97 (95% CI = 0.949,
0.997) for a unit increase in cm2 of BSA i.e. a higher BSA
had a reduced hazard of haematological toxicity at any
time. Some of the other grade 3 or 4 adverse events are
detailed in Table 3.
Secondary Endpoints
Pharmacokinetics and Radioactivity
Following administration of the pre therapy dose,
KAb201 levels peaked at 10 minutes post administration,
then declined steadily and levels were undetectable by
one week. After the therapy dose, maximal activity was
seen up to 5 days post treatment, with subsequent gradual
decline and was undetectable by 1 to 2 months (Figure 2).
Radioactivity levels changes were similar to the study drug
pharmacokinetic data (Figure 3).
Employing the single compartment model, the popula-
tion volume of distribution (V) was similar in the intra-
arterial and the intravenous arms (Table 4 and Table 5) for
both the therapy dose of KAb201 and radioactivity. The
population elimination rate was significantly higher (p <
0.001) for the intravenous group compared with the intra-
arterial group for both the therapy dose of KAb201 and
radioactivity level.
Antigenicity
HACA antibodies developed in all 16 assessable patients.
In two patients who could not be assessed, the sample was
insufficient for analysis in one and in the other only a
screening sample was available.
17/17 (100%) patients developed HASA antibodies. One
patient could not be assessed for this parameter as only
the screening sample was available.
Efficacy
Eighteen patients were assessable for efficacy analyses.
There was one partial response, one stable disease, and 16
Dose limiting toxicity Figure 1
Dose limiting toxicity. In the intra-arterial arm dose limit-
ing toxicity (DLT) was observed in two of three patients at 
50 mCi in the first cohort and in none of the three patients 
each in both the second cohort (45 mCi) and the third 
cohort (50 mCi). In the intravenous arm, one out of three 
patients experienced DLT at 50 mCi and none out of the 
three patients each in the second (50 mCi) and third cohorts 
(75 mCi) suffered a DLT. In summary, 2/6 patients experi-
enced DLT in the intra-arterial arm (MTD reached at 50 
mCi) and 1/6 patients in the intravenous arm (MTD not 
reached).BMC Cancer 2009, 9:66 http://www.biomedcentral.com/1471-2407/9/66
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Table 3: Grade 3 or 4 drug related adverse events
Event Intra-arterial
(n = 9)
Intra-venous
(n = 9)
Total
(n = 18)
Lymphopenia 3 2 5
Thrombocytopenia 4 2 6
Leukopenia 4 0 4
Neutropenia 3 0 3
Sepsis 1 1 2
Vomiting 1 1 2
Alanine aminotransferase 1 0 1
Anaemia 0 1 1
Anorexia 0 1 1
Aspartate aminotransferase 1 0 1
Blood alkaline phosphatase 1 0 1
Febrile neutropenia 1 0 1
Haematemesis 0 1 1
Neutrophilia 1 0 1
Thrombosis 1 0 1
Pharmacokinetics- Post treatment with KAb201 Figure 2
Pharmacokinetics- Post treatment with KAb201. The pharmacokinetics of KAb201 per individual patient (n = 18). After 
administration of the therapy dose, maximal levels (ng/ml) in blood were seen up to 5 days post treatment, with subsequent 
gradual decline and undetectable level by 1–2 months.BMC Cancer 2009, 9:66 http://www.biomedcentral.com/1471-2407/9/66
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patients progressed. This yields an overall response rate of
6% and disease control rate of 11% (Disease control rate
= partial response+ stable disease).
Overall Survival
For all 19 patients, median (95% CI) overall survival was
5.2 (3.3 to 9) months. There was no significant overall
survival difference between the intravenous and intra-
arterial arms (log rank p = 0.79). One patient was still
alive at the time of this analysis (08 May 2006), at 13
months post-therapy.
Patients with KPS scores of 90/100 survived longer than
those with KPS of 70/80 (log rank p = 0.07; Figure 4).
There was no difference in survival between patients with
locally advanced and metastatic disease (log rank p =
0.93) and in those with or without prior treatment (log
rank p = 0.34).
Discussion
The maximum tolerated dose of 50 mCi by the intra-arte-
rial arm in the present study is difficult to compare with
the results of other studies, as we did not dose patients
based on their body surface area. Being a phase I explora-
tory study, we used pre-specified dose levels in terms of
mCi. However, on post-hoc review of the dose based on
body surface area, patients in whom dose limiting toxicity
was seen i.e. those administered 50 mCi by the intra-arte-
rial route received a median dose of 27.5 mCi/m2. This is
lower than the maximum tolerated dose of 60 mCi/m2
reported by Behr et al [16], as well as the 40 mCi/m2
found by Hajjar et al [29].
Surprisingly, despite the loco- regional nature of delivery
of KAb201, systemic toxicity occurred. Directly labelled
monoclonal antibodies are known to have a relatively low
level of uptake in solid tumours, and additionally ham-
pered by heterogeneous deposition of the antibody as
well as radiation doses in tumour tissue [30]. The
unbound radiolabelled KAb 201 circulating systemically
is likely to be responsible for the toxicity observed.
By the intravenous route, a larger dose of radiation, up to
75 mCi at close of trial, equating to a median of 45 mCi/
m2, could be delivered without causing dose limiting tox-
icity. The haematological toxicity seen is in keeping with
previous reports, which also reported myelotoxicity to be
the main dose limiting factor [16,31,32]. Dosimetry based
planning of treatment and pretargeting may minimise this
problem [31]. Since the aim of this phase I trial was to
determine the MTD for KAb 201 with I131 and the therapy
doses were planned as per protocol, we did not use formal
dosimetry.
A poor correlation between the toxicity grade and admin-
istered radioactive dose has been reported, leading to the
conclusion that factors other than the total administered
activity or the bone marrow dose are important [32]. The
incidence of systemic toxicity in the intra-arterial arm
implies that despite the loco regional delivery, there is
spill over into the systemic circulation, supported by the
finding of similar volume of distribution in both arms.
The earlier occurrence of haematological toxicity in the
intra-arterial arm could be linked to the slower rate of
elimination seen in this arm, compared to the intravenous
arm.
The similar pharmacokinetics of KAb201 and I131 implies
it was appropriate to combine these two agents, as their
decline runs in parallel. In view of the fact that the levels
Pharmacokinetics- Post-therapy dose blood radioactivity of  I131 levels Figure 3
Pharmacokinetics- Post-therapy dose blood radioac-
tivity of I131 levels. The pharmacokinetics of I131 per individ-
ual patient (n = 18). Radioactivity levels (MBq = mega 
bequerel) following administration of the therapy dose were 
high in the first five days, with levels gradually declining there-
after, to near undetectable levels in blood by 2 months.
Table 4: Pharmacokinetic analysis- Population estimates for the therapeutic dose of I131 KAb201.
Parameter Intra-arterial group Intravenous group
Volume of distribution mean (SE) 0.0032 (0.0004) L 0.0031 (0.0003) L
Elimination rate mean (SE) 0.0944 (0.0095) litres/hour 0.1498 (0.0176) litres/hour
Area under Curve mean (range) 15801.0 (5673.4, 30011.2) ng/ml 12411.3 (4748.3, 20713.8) ng/ml
Cmax mean (range) 1488.7 (644.5, 2328.5) ng/ml 1812.7 (1002.8, 2600.3) ng/ml
SE = standard error; L = litre; h = hour; ng = nanogram; ml= millilitresBMC Cancer 2009, 9:66 http://www.biomedcentral.com/1471-2407/9/66
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reach near undetectable levels by 6–8 weeks in most
patients, this time point, rather than the 3 months chosen
at start of study, may be more appropriate for either a
repeat dose or commencement of palliative treatment off-
trial.
The antigenic response seen in the majority of patients to
both the sheep and chimaeric component of the antibody
limits the possibility of repeat dosing, as this may either
lead to hypersensitivity reactions or complexing with cir-
culating antibody, making it difficult or impossible to
maintain effective therapeutic levels [15]. Repeat dosing
using high affinity humanised monoclonal anti-CEA anti-
body have been reported [16,33].
Similar to our antigenicity result, Ritter et al, despite using
a humanised murine monoclonal antibody, detected
human anti-human antibodies (HAHA) in 63% of
patients treated with repeat dosing [33]. They suggest that
monitoring the type of antibody helped them single out
patients at risk for transfusion-related adverse events, as
those who developed type I HAHA (characterised by early
onset, with levels peaking after 2 weeks and declining
thereafter) did not develop infusion-related adverse
events, unlike patients with type II antibodies (onset
delayed, with levels increasing following repeat dosing).
The overall response rate of 6% is similar to that reported
using single agent gemcitabine by Burris et al (5.4%) [6],
as well as in two other large studies by Cunningham et al
(7%) [34] and Moore et al (9%) [8].
The effectiveness of monoclonal antibodies has been lim-
ited by low quantitative delivery to tumours, poor diffu-
sion from vasculature into tumour and biodistribution to
normal organs [10]. Although tumour vessels have
attributes that favour movement of molecules across the
vessels such as wide inter-endothelial junctions, large
number of fenestrae and discontinuous or absent base-
ment membrane, these are offset by the high interstitial
pressure and low microvascular pressure that may retard
extravasation of molecules, particularly into large
tumours [35]. Other factors limiting efficacy may be
inherent radio-resistance and heterogenous expression of
CEA [36].
Our study's median overall survival of 5.2 months is com-
parable to that achieved by single agent gemcitabine in
several trials of 4.0–5.2 months [6,37,38], and somewhat
inferior to the median survival of 6.0 to 7.3 months in the
single agent gemcitabine arm in some others [34,39-41]).
Survival with I131 KAb201 may be boosted by combina-
tion with chemotherapy, which may also help radiosensi-
tize the tumour. The chemotherapy suggested, based on a
recent meta-analysis, is gemcitabine based combination
chemotherapy [7]. Alternatively, to avoid further increas-
ing marrow toxicity, combination with erlotinib may help
improve its effectiveness.
Conclusion
In summary, KAb201 with I131 demonstrated tumour tar-
geting, with haematological toxicity of varying degrees.
The intra-arterial route did not confer any additional sur-
Table 5: Pharmacokinetic analysis- Population estimates for radioactivity following administration of the therapeutic dose of I131 
KAb201.
Parameter Intra-arterial group Intravenous group
Volume of distribution mean(SE) 0.0600 (0.0048) L 0.0611 (0.0024) L
Elimination rate mean(SE) 0.1461 (0.0179) litres/hour1 0.1992 (0.0224) litres/hour
Area under Curve mean (range) 5509.0 (3245.3, 11049.7) ng/ml 4854.9 (3482.6, 6272.5) ng/ml
Cmax mean (range) 806.0 (608.8, 1191.4) ng/ml 982.2 (754.4, 1386.9) ng/ml
SE = standard error; L = litre; h = hour; ng = nanogram; ml= millilitres.
Overall survival stratified by Karnofsky Performance Status Figure 4
Overall survival stratified by Karnofsky Performance 
Status. This is a Kaplan Meir survival curve of all 19 patients, 
stratified by their Karnofsky Performance Status i.e. KPS 90/
100 versus KPS 70/80. The trend towards improved survival 
in the higher KPS group was not statistically significant (log 
rank p = 0.07).BMC Cancer 2009, 9:66 http://www.biomedcentral.com/1471-2407/9/66
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vival benefit or reduction in toxicity over the intravenous
route, with a dose limiting toxicity at 50 mCi. Survival and
efficacy data is comparable to the median survival and
efficacy seen with single agent gemcitabine. The antigenic
response observed with KAb 201 may raise questions over
its suitability for repeated dosing. Investigation of the type
of antibody response (type I or type II) in future studies
may lead to the ability to predict those patients who are
likely to suffer a transfusion related adverse event on
repeat dosing. Humanisation of the antibody instead of
the current human sheep chimaeric construct may reduce
the immunogenicity.
Although RIT has been successful in the setting of lym-
phoma, the low therapeutic index observed with the one
stage RIT approach have failed to produce equivalent anti-
tumour effects in the more radio resistant solid tumours
(referenced in [42,43]. As the tumour uptake, and thereby
the radiation dose, is inversely related to tumour size [31],
KAb201 may be a viable option in small volume meta-
static disease. In view of the low toxicity seen in the intra-
venous arm, allowing dose escalation of up to 75 mCi, it
may be feasible to combine KAb201 with I131 given by the
intravenous route with chemotherapy, as has been dem-
onstrated in a preclinical study [44], or erlotinib, to
improve efficacy.
Abbreviations
AE: adverse event; BSA: body surface area; CEA: carcino-
embryonic antigen; CI: confidence interval; CT: computed
tomography; CTC: Common Toxicity Criteria; DLT: dose
limiting toxicity; HACA: human anti-chimaeric antibody;
HAHA: human anti-human antibody; HASA: human anti-
sheep antibody; I131: iodine 131; HR: hazard ratio; KPS:
Karnofsky performance status; MBq: mega Bequerel; mCi:
milli Curie; MTD: maximum tolerated dose; PET: positron
emission tomography; RECIST: Response Evaluation Cri-
teria in Solid Tumours; RIT: radioimmunotherapy;
SPECT: single photon emission computerised tomogra-
phy scans.
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